Propofol inhibits renal cytochrome P450 activity and enflurane defluorination in vitro in hamsters.
OBJECTIVE
To determine the effect of propofol on renal cytochrome P450 activity and defluorination of enflurane.


METHODS
Renal microsomes were prepared by homogenization and differential centrifugation from pooled hamster kidneys. Defluorination of enflurane was assessed by measuring free fluoride metabolites after reacting enflurane with renal microsomes incubated with various concentrations, 0.05 - 1.0 mmol x L(-1) propofol in the NADPH-generating system. Drug metabolizing activities of renal cytochrome P450 mono-oxygenase enzymes were evaluated within microsomes preincubated with propofol and reacted with the specific marker substrates, aniline, benzo(a)pyrene, erythromycin and pentoxyresorufin, for cytochrome P450 2E1, 1A1, 3A4 and 2B1, respectively.


RESULTS
Renal defluorination of enflurane was inhibited by clinical concentrations, 0.05 mmol x L(-1) of propofol (P < 0.05). Dose-dependent inhibition of defluorination, aniline and benzo(a)pyrene hydroxylase within kidney microsomes was related to propofol concentration. Propofol demonstrated a profound inhibition of renal pentoxyresorufin dealkylase activity even at low concentrations, 0.05 mmol x L(-1) (P < 0.01). Propofol did not exhibit inhibition of erythromycin N-demethylation of kidney microsomes except at high concentration, 1.0 mmol x L(-1). Spectral analyses of key coenzymes of renal cytochrome P450 monooxygenase, cytochrome b5 and cytochrome c reductase, demonstrated an inhibition when incubated with high concentrations of propofol (P < 0.05).


CONCLUSIONS
In an in vitro study in an NADPH-generating system of hamster kidney microsomes, propofol, in clinical concentrations, exhibited a broad-spectrum of inhibition to renal monooxygenase activities and enflurane defluorination.
Chen
T L
TL
Department of Anesthesiology, Taipei Medical College, Wan-Fang Hospital, Taiwan. tlc@tmc.edu.tw
Chen
T G
TG
Tai
Y T
YT
Chang
H C
HC
Chen
R M
RM
Lin
C J
CJ
Ueng
T H
TH
D018685:Anesthetics, Inhalation / Q000378:metabolism*; D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D000814:Aniline Compounds / Q000378:metabolism; D000818:Animals; D001564:Benzo(a)pyrene / Q000378:metabolism; D006224:Cricetinae; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D015786:Cytochromes b5 / Q000037:antagonists & inhibitors / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004737:Enflurane / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005461:Fluorine / Q000378:metabolism; D006900:Hydroxylation / Q000187:drug effects; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D008647:Mesocricetus; D008861:Microsomes / Q000187:drug effects / Q000201:enzymology; D009245:NADH Dehydrogenase / Q000037:antagonists & inhibitors / Q000378:metabolism; D009249:NADP / Q000037:antagonists & inhibitors / Q000378:metabolism; D015742:Propofol / Q000494:pharmacology*; D015203:Reproducibility of Results
D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D000814:Aniline Compounds; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D005461:Fluorine; D001564:Benzo(a)pyrene; D009249:NADP; D015786:Cytochromes b5; D003577:Cytochrome P-450 Enzyme System; D004737:Enflurane; D009245:NADH Dehydrogenase; D015742:Propofol